BioSpace News Archive

United Therapeutics Corporation announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram® (treprostinil) extended-release tablets in patients suffering from pulmonary arterial hypertension (PAH) has met its primary endpoint of delayed time to first clinical worsening event.

Second Quarter 2018 Highlights

Improvements in formulary status for key products

MRIGlobal has been awarded a 5-year, $19.9 million contract from the National Institutes of Health (NIH)/National Cancer Institute (NCI)/Division of Cancer Prevention to continue to operate the Centralized Chemopreventive Agent Repository and Drug Chemistry Support program.

MedEquities Realty Trust, Inc. announced its consolidated financial results for the quarter ended June 30, 2018 and other recent developments.

Paper identifies chief cloud security risks, how they fit in a greater security analysis

TIENS Group, one of leading corporations in the Healthcare industry, unveiled a new high-tech Customer Experience Store in Shenzhen.

Acquisition to Bolster Company’s Venous Therapies Portfolio within Peripheral Interventions Division

Second Quarter Year-over-Year Highlights

Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018